[The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases].
The use is studied of the immunomodulating agents splenin and vilosen in a combined therapy of 93 patients with chronic cholestatic disorders of the liver. The above drug combination was found to have a positive effect on both the immune status and condition of microhemodynamics, with the clinical parameters getting improved, duration of remission lengthened.
Petrunia
A M
AM
Enenko
Iu A
IuA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006505:Hepatitis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013154:Spleen; D013946:Thymopoietins / Q000627:therapeutic use*; D013949:Thymus Extracts / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D013946:Thymopoietins; D013949:Thymus Extracts; C059606:iilozen; C032841:thymopoietin III